Specifically, the classification of molecular subtypes in breast cancer (luminal A/B, triple-negative breast cancer or TNBC, and HER2 amplified breast cancer) based on gene and protein expression has provided a level of refinement in patient stratification and therapeutic decision making. The gene discussed is ERBB2; the disease is breast carcinoma.